Pfizer Inc. Release: New Exubera Data To Be Presented At American Diabetes Association Meeting

NEW YORK, June 9 /PRNewswire-FirstCall/ -- A New Medicine for People With Diabetes: Exubera® (insulin human (rDNA origin)) is a rapid-acting dry powder human insulin inhaled through the mouth into the lungs prior to eating using the Exubera Inhaler. The patient inserts an Exubera blister into the inhaler, and with the press of a lever and a button, an insulin cloud is released into the inhaler chamber. The patient breathes in normally, sending the insulin into the lungs and then the bloodstream. Exubera was approved earlier this year in the United States and in the European Union for adults with type 1 and type 2 diabetes.